JP2017515839A5 - - Google Patents

Download PDF

Info

Publication number
JP2017515839A5
JP2017515839A5 JP2016567385A JP2016567385A JP2017515839A5 JP 2017515839 A5 JP2017515839 A5 JP 2017515839A5 JP 2016567385 A JP2016567385 A JP 2016567385A JP 2016567385 A JP2016567385 A JP 2016567385A JP 2017515839 A5 JP2017515839 A5 JP 2017515839A5
Authority
JP
Japan
Prior art keywords
formulation
brain
nanoparticle
polymer
hydrophilic polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016567385A
Other languages
English (en)
Japanese (ja)
Other versions
JP6763780B2 (ja
JP2017515839A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/030381 external-priority patent/WO2015175539A1/en
Publication of JP2017515839A publication Critical patent/JP2017515839A/ja
Publication of JP2017515839A5 publication Critical patent/JP2017515839A5/ja
Application granted granted Critical
Publication of JP6763780B2 publication Critical patent/JP6763780B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016567385A 2014-05-12 2015-05-12 合成脳浸透遺伝子ベクターの操作 Active JP6763780B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461991898P 2014-05-12 2014-05-12
US201461991920P 2014-05-12 2014-05-12
US61/991,920 2014-05-12
US61/991,898 2014-05-12
US201462001994P 2014-05-22 2014-05-22
US62/001,994 2014-05-22
PCT/US2015/030381 WO2015175539A1 (en) 2014-05-12 2015-05-12 Engineering synthetic brain penetrating gene vectors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020116339A Division JP2020172534A (ja) 2014-05-12 2020-07-06 合成脳浸透遺伝子ベクターの操作

Publications (3)

Publication Number Publication Date
JP2017515839A JP2017515839A (ja) 2017-06-15
JP2017515839A5 true JP2017515839A5 (enExample) 2018-04-26
JP6763780B2 JP6763780B2 (ja) 2020-09-30

Family

ID=53264811

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016567385A Active JP6763780B2 (ja) 2014-05-12 2015-05-12 合成脳浸透遺伝子ベクターの操作
JP2020116339A Pending JP2020172534A (ja) 2014-05-12 2020-07-06 合成脳浸透遺伝子ベクターの操作

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020116339A Pending JP2020172534A (ja) 2014-05-12 2020-07-06 合成脳浸透遺伝子ベクターの操作

Country Status (6)

Country Link
US (3) US9937270B2 (enExample)
EP (1) EP3142704A1 (enExample)
JP (2) JP6763780B2 (enExample)
AU (1) AU2015259362B2 (enExample)
CA (1) CA2948844C (enExample)
WO (1) WO2015175539A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011106702A2 (en) 2010-02-25 2011-09-01 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
WO2017044759A1 (en) * 2015-09-11 2017-03-16 The Johns Hopkins University Compositions and methods to improve nanoparticle distribution within the brain interstitium
WO2020210805A1 (en) * 2019-04-11 2020-10-15 The Johns Hopkins University Nanoparticles for drug delivery to brain
CN111658785B (zh) * 2020-04-21 2023-05-12 威爱医疗科技(中山)有限公司 一种基因载体及其制备方法和应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5527675A (en) 1993-08-20 1996-06-18 Millipore Corporation Method for degradation and sequencing of polymers which sequentially eliminate terminal residues
DE4331012A1 (de) 1993-09-13 1995-03-16 Bayer Ag Nukleinsäuren-bindende Oligomere mit N-Verzweigung für Therapie und Diagnostik
US5786571A (en) 1997-05-09 1998-07-28 Lexmark International, Inc. Wrapped temperature sensing assembly
US6509323B1 (en) 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
CA2406081C (en) 2000-04-26 2009-12-22 Oregon Health Sciences University Administration of a thiol-based chemoprotectant compound
AU2001271345A1 (en) 2000-07-10 2002-01-21 Albert T. Naito Method for opening the blood-brain barrier
RU2322500C2 (ru) 2000-12-01 2008-04-20 Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. Малые молекулы рнк, опосредующие интерференцию рнк
EP1648914A4 (en) 2003-07-31 2009-12-16 Regulus Therapeutics Inc OLIGOMERIC COMPOUNDS AND COMPOSITIONS USEFUL FOR MODULATING SMALL NON-CODING RNA
US8969314B2 (en) 2003-07-31 2015-03-03 Regulus Therapeutics, Inc. Methods for use in modulating miR-122a
US20050142581A1 (en) 2003-09-04 2005-06-30 Griffey Richard H. Microrna as ligands and target molecules
US20080213891A1 (en) 2004-07-21 2008-09-04 Alnylam Pharmaceuticals, Inc. RNAi Agents Comprising Universal Nucleobases
US7579451B2 (en) 2004-07-21 2009-08-25 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a modified or non-natural nucleobase
WO2006112872A2 (en) 2004-08-04 2006-10-26 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase
US20060223777A1 (en) 2005-03-29 2006-10-05 Dharmacon, Inc. Highly functional short hairpin RNA
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
AU2006279906B2 (en) 2005-08-10 2012-05-10 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
WO2007027894A2 (en) 2005-08-29 2007-03-08 Isis Pharmaceuticals, Inc. Antisense compounds having enhanced anti-microrna activity
US8658608B2 (en) 2005-11-23 2014-02-25 Yale University Modified triple-helix forming oligonucleotides for targeted mutagenesis
EP2388327A1 (en) 2006-01-27 2011-11-23 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of micrornas
KR101407707B1 (ko) 2006-04-03 2014-06-19 산타리스 팔마 에이/에스 Ａｎｔｉ-ｍｉｒｎａ 안티센스 올리고뉴클레오타이드를 함유하는 약학적 조성물
JP2008053276A (ja) 2006-08-22 2008-03-06 Nec Electronics Corp 半導体装置の製造方法
EP2090665A2 (en) 2006-10-20 2009-08-19 Exiqon A/S Novel human microRNAs associated with cancer
US20090137504A1 (en) 2006-12-21 2009-05-28 Soren Morgenthaler Echwald Microrna target site blocking oligos and uses thereof
US20110262406A1 (en) 2010-04-21 2011-10-27 Yale University Compositions and methods for targeted inactivation of hiv cell surface receptors
WO2012039979A2 (en) 2010-09-10 2012-03-29 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
CA2819635A1 (en) * 2010-12-01 2012-06-07 Spinal Modulation, Inc. Directed delivery of agents to neural anatomy
WO2012109363A2 (en) * 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
CN107982548A (zh) * 2012-02-07 2018-05-04 全球生物疗法有限公司 核酸输送的区室化方法及其组合物和应用

Similar Documents

Publication Publication Date Title
da Silva et al. New perspectives in nanotherapeutics for chronic respiratory diseases
AU2016200683B2 (en) Nanoparticles with enhanced mucosal penetration or decreased inflammation
Ghalamfarsa et al. Application of nanomedicine for crossing the blood–brain barrier: Theranostic opportunities in multiple sclerosis
Liu et al. Dendrimers in oral drug delivery application: current explorations, toxicity issues and strategies for improvement
JP6387400B2 (ja) 医薬組成物、その製造および使用
Shah et al. Intranasal delivery: An attractive route for the administration of nucleic acid based therapeutics for CNS disorders
JP2017515839A5 (enExample)
Mayilsamy et al. Treatment with shCCL20-CCR6 nanodendriplexes and human mesenchymal stem cell therapy improves pathology in mice with repeated traumatic brain injury
Zhao et al. Intranasal immunization with O-2′-Hydroxypropyl trimethyl ammonium chloride chitosan nanoparticles loaded with Newcastle disease virus DNA vaccine enhances mucosal immune response in chickens
JP2016513090A5 (enExample)
Chandra et al. Combining unique properties of dendrimers and magnetic nanoparticles towards cancer theranostics
JP2018533579A5 (enExample)
US20150079007A1 (en) Tunable multimodal nanoparticles and methods of use thereof
Xin et al. Evaluation of rMETase-loaded stealth PLGA/liposomes modified with anti-CAGE scFV for treatment of gastric carcinoma
US20170258718A1 (en) Pharmaceutical composition, preparation and uses thereof
WO2016128591A1 (es) Procedimiento de obtención de una composición farmacéutica de nanopartículas poliméricas para el tratamiento del dolor neuropático producido por compresión nerviosa periférica
CN110139826A (zh) 具有负的表面电荷的微粒和纳米颗粒
Doroudian et al. Nano-based therapies for acute and chronic lung diseases
Ravinayagam et al. Nanomaterials and their negative effects on human health
Edward Werner et al. Chemoradiotherapy of human tumors: novel approaches from nanomedicine
JP2018534244A5 (enExample)
CN112566627A (zh) 用于递送病毒的高分子纳米粒子组合物及其制造方法
Rathi et al. Treatment of tuberculosis in nano era: recent avenues
CN118697901A (zh) 一种吸入式IL-10 mRNA纳米制剂及其制备方法和应用
JP6661700B2 (ja) タキサンを含有するナノ粒子およびその使用